Immune monitoring after cell therapy and hematopoietic cell transplantation: Guidelines by the ISCT Stem Cell Engineering Committee Review
| Authors: | Oppizzi, L.; Hosszu, K.; Prockop, S.; Bidgoli, A.; Bonfim, C.; Ciccocioppo, R.; Ruggeri, A.; Maiers, M.; Bertaina, A.; Boelens, J. J. |
| Review Title: | Immune monitoring after cell therapy and hematopoietic cell transplantation: Guidelines by the ISCT Stem Cell Engineering Committee |
| Abstract: | Allogeneic hematopoietic cell transplantation and cell therapy (TCT) are potentially lifesaving treatments for patients with high-risk hematologic malignancies and life-threatening acquired and genetic hematologic disorders. However, these treatments face significant challenges, particularly in the risks of relapse and severe toxicity, leading to both relapse-related and non-relapse mortality (NRM). The immune system plays a critical role in controlling these risks, but predictive immune biomarkers for relapse and toxicity have yet to be fully established. To better understand factors driving outcomes in TCT recipients, researchers are increasingly relying on minimally invasive specimens for analysis, such as peripheral blood. These liquid biopsies provide a cost-effective and rapid means to evaluate parameters such as minimal residual disease and genomic mutation profiles. The evolution of these techniques opens new possibilities for monitoring immune reconstitution, including tracking immune cell development and the diversity of surface and secreted biomarkers. This review presents a practical guideline for establishing an immune monitoring program tailored to the TCT environment. By adopting a proactive, harmonized approach, such programs can enhance prognosis prediction and enable early relapse detection, potentially surpassing traditional diagnostic methods. While recent advancements are promising, considerable progress is still needed to make liquid biopsies a routine component of clinical practice. © 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. © 2025 International Society for Cell & Gene Therapy |
| Keywords: | clinical trial; review; clinical practice; biological marker; immune system; practice guideline; prediction; stem cell; hematologic malignancy; drug combination; minimal residual disease; gene therapy; hematopoietic cell; cell therapy; immunological monitoring; clinical practice guideline; immunosurveillance; therapy; immunocompetent cell; cell transplantation; transplantation immunology; immune reconstitution; histocompatibility; genomic mutation; cell engineering; human; liquid biopsy; cytogenesis; cellular biomarkers; functional immune recovery; immune monitoring program |
| Journal Title: | Cytotherapy |
| Volume: | 27 |
| Issue: | 8 |
| ISSN: | 1465-3249 |
| Publisher: | Elsevier Science Ltd. |
| Publication status: | Published |
| Date Published: | 2025-08-01 |
| Start Page: | 888 |
| End Page: | 902 |
| Language: | English |
| DOI: | 10.1016/j.jcyt.2025.04.069 |
| PROVIDER: | scopus |
| PMCID: | PMC12265769 |
| PUBMED: | 40493000 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Kinga Hosszu -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work